Semi‐Mechanistic PK/PD Modeling and Simulation of Irreversible BTK Inhibition to Support Dose Selection of Tirabrutinib in Subjects with RA

Tirabrutinib is an irreversible, small‐molecule Bruton’s tyrosine kinase (BTK) inhibitor, which was approved in Japan (VELEXBRU) to treat B‐cell malignancies and is in clinical development for inflammatory diseases. As an application of model‐informed drug development, a semimechanistic pharmacokine...

Descripción completa

Detalles Bibliográficos
Autores principales: Meng, Amy, Humeniuk, Rita, Jürgensmeier, Juliane M., Hsueh, Chia‐Hsiang, Matzkies, Franziska, Grant, Ethan, Truong, Hoa, Billin, Andrew N., Yu, Helen, Feng, Joy, Kwan, Ellen, Tarnowski, Thomas, Nelson, Cara H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298258/
https://www.ncbi.nlm.nih.gov/pubmed/34623640
http://dx.doi.org/10.1002/cpt.2439

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298258/
https://www.ncbi.nlm.nih.gov/pubmed/34623640
http://dx.doi.org/10.1002/cpt.2439

Ejemplares similares